Table 2.

Replication evidence for association with prostate cancer among published loci.

					Minor Allele Heterozygote					Minor Allele Homozygote
Chr	Gene	Variant			Case	Control	OR	95% CI	P	Case	Control	OR	95% CI	P
2p15	(GWAS)	rs721048		T	176	157	1.32	1.00 – 1.73	0.047	41	11	4.06	2.07 – 7.98	4.7 × 10−5
8q24 cen.	(GWAS)	rs6983267		T	225	252	0.65	0.49 – 0.87	0.0040	100	138	0.49	0.34 – 0.70	7.5 × 10−5
8q24 cen.	POU5F1P1	rs6998061	G527E	A	218	236	0.75	0.58 – 0.98	0.032	79	108	0.56	0.39 – 0.80	0.0015
8q24 tel.	(GWAS)	rs1447295		A	133	85	1.78	1.30 – 2.44	2.9 × 10−4	7	3	2.36	0.60 – 9.21	0.22
11q13	(GWAS)	rs10896450		A	247	256	0.72	0.54 – 0.96	0.024	89	128	0.51	0.35 – 0.73	2.2 × 10−4
1q25	RNASEL	rs11807829		C	240	227	1.06	0.81 – 1.37	0.67	49	60	0.83	0.54 – 1.27	0.39
		rs533259		T	68	71	0.94	0.64 – 1.37	0.74	3	2	1.48	0.25 – 8.90	0.67
		rs627928	E541D	T	262	253	0.91	0.69 – 1.21	0.52	81	110	0.64	0.44 – 0.92	0.018
		rs486907	R462Q	A	259	228	1.34	1.03 – 1.76	0.031	76	73	1.22	0.84 – 1.78	0.29
2q13	IL1RN	rs2637988		G	235	248	0.89	0.68 – 1.16	0.37	79	80	0.92	0.63 – 1.34	0.67
		rs3213448		A	94	94	1.01	0.74 – 1.38	0.94	5	11	0.47	0.16 – 1.35	0.16
		rs3087263		A	96	93	1.03	0.75 – 1.41	0.87	7	10	0.70	0.26 – 1.84	0.47
		rs380092		T	208	218	0.95	0.73 – 1.22	0.67	53	48	1.10	0.72 – 1.67	0.67
		rs315952		C	194	204	0.93	0.72 – 1.20	0.58	44	43	1.00	0.64 – 1.57	0.98
3p25	PPARG*	rs1805192	P12A	C	0	0				0	0
		rs1801282	P12A**	G	105	114	0.92	0.68 – 1.24	0.58	8	3	2.66	0.69 – 10.17	0.15
4p14	TLR10*	rs4129009	I775V	G	145	167	0.83	0.63 – 1.08	0.17	22	18	1.15	0.60 – 2.21	0.67
		rs11466658	R525W	T	28	26	1.08	0.62 – 1.88	0.79	0	0
		rs11096955	I369L	C	214	221	0.93	0.72 – 1.21	0.60	67	71	0.90	0.62 – 1.32	0.60
		rs11096957	N241H	C	214	221	0.93	0.72 – 1.20	0.58	67	71	0.88	0.60 – 1.30	0.53
4p14	TLR1	rs3923647	H305L	T	30	28	1.07	0.63 – 1.83	0.80	0	0
		rs4833095	N248S	C	181	198	0.88	0.68 – 1.13	0.30	33	31	1.00	0.59 – 1.67	0.98
		rs5743611	R80T	C	69	74	0.93	0.65 – 1.32	0.67	5	7	0.80	0.25 – 2.56	0.71
4p14	TLR6	rs5743815	V427A	C	21	12	1.75	0.86 – 3.57	0.13	0	0
		rs5743810	P249S	T	264	256	1.08	0.81 – 1.44	0.58	99	101	1.02	0.71 – 1.45	0.91
		rs1039559		C	265	253	1.14	0.86 – 1.53	0.36	125	125	1.10	0.78 – 1.54	0.60
7q32	PODXL*	rs3735035	G112S	T	272	271	0.90	0.67 – 1.21	0.48	109	122	0.80	0.56 – 1.14	0.21
		rs3212298	V358I	A	45	60	0.71	0.47 – 1.07	0.10	2	2	0.94	0.13 – 6.84	0.95
7q36	EZH2*	rs2302427	D185H	C	69	98	0.63	0.44 – 0.89	0.0085	4	5	0.67	0.18 – 2.56	0.56
8p21	NKX3-1	rs1567669		T	201	244	0.71	0.55 – 0.92	0.010	55	51	0.93	0.61 – 1.42	0.74
9q33	TLR4	rs11536869		G	43	41	1.02	0.66 – 1.60	0.91	0	2
		rs1927911		T	196	212	0.92	0.71 – 1.19	0.52	47	35	1.38	0.84 – 2.29	0.21
		rs11536879		G	45	32	1.47	0.91 – 2.38	0.12	0	1
		rs5030717		G	110	107	1.02	0.75 – 1.38	0.91	3	4	0.72	0.12 – 4.34	0.72
		rs5030728		A	225	237	0.90	0.70 – 1.15	0.41	44	47	0.86	0.55 – 1.36	0.53
		rs4986791	T399I	T	53	59	0.88	0.59 – 1.32	0.55	2	1	1.74	0.15 – 19.63	0.65
10q24	CYP17A1	rs10883783		A	226	222	1.09	0.85 – 1.40	0.52	55	42	1.36	0.89 – 2.09	0.16
		rs3824755		C	79	95	0.81	0.58 – 1.12	0.19	2	4	0.53	0.10 – 2.92	0.47
		rs6163		A	249	240	1.10	0.85 – 1.43	0.46	85	83	1.08	0.75 – 1.56	0.67
		rs2486758		C	174	161	1.13	0.87 – 1.49	0.36	21	22	1.00	0.54 – 1.84	1.00
12p13	CDKN1B	rs34329		G	225	227	0.99	0.76 – 1.28	0.92	48	46	1.04	0.67 – 1.61	0.85
		rs3093736		A	30	34	0.89	0.54 – 1.46	0.65	0	0
16q22	CDH1*	rs16260	5'(−160A)	A	201	211	0.97	0.75 – 1.25	0.81	45	37	1.21	0.77 – 1.91	0.41
15q24	CYP1A1	rs4646421		T	96	83	1.21	0.86 – 1.70	0.27	3	6	0.55	0.14 – 2.22	0.40
17p12	ELAC2*	rs4792311	S217L	A	224	216	1.08	0.84 – 1.40	0.56	46	42	1.13	0.73 – 1.74	0.60
19q13	TGFB1*	rs1800470	L10P	C	242	239	0.96	0.73 – 1.27	0.79	66	78	0.76	0.51 – 1.12	0.16

^*candidate, rather than tagging SNPs evaluated.

^**different residue variant from an alternative transcript.